Management of viral hepatitis in patients with hepatocellular carcinoma.
10.5124/jkma.2013.56.11.1001
- Author:
Jeong Won JANG
1
Author Information
1. Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. garden@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Hepatitis B virus;
Hepatitis C virus;
Hepatocellular carcinoma;
Management
- MeSH:
Carcinoma, Hepatocellular*;
Disease Progression;
Fibrosis;
Hepacivirus;
Hepatitis B virus;
Hepatitis*;
Humans;
Inflammation;
Liver Cirrhosis;
Liver Diseases;
Recurrence;
Tertiary Prevention
- From:Journal of the Korean Medical Association
2013;56(11):1001-1011
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Globally, viral hepatitis due to hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection is the major cause of advanced liver diseases such as liver cirrhosis and hepatocellular carcinoma (HCC). Chronic inflammation resulting from persistent viral hepatitis is also associated with an increased risk of HCC recurrence. Replication of HBV and/or HCV can reactivate during anti-cancer treatments of HCC and lead to hepatic dysfunction, adversely affecting patient outcomes. The most effective way to prevent chronic viral hepatitis, cirrhosis, or HCC would be the implementation of a vaccine. Unfortunately, a vaccine for HCV is currently not available. For chronically infected patients, antiviral therapy may be the only option that can prevent or retard disease progression. Emerging evidence continues to support direct or indirect benefits from antiviral therapy for preventing liver disease progression to cirrhosis, HCC development, and recurrence after curative treatments in patients with chronic HBV or HCV infection. This paper reviews the literature on the management of viral hepatitis in patients with HCC, focusing on primary and tertiary prevention of HCC.
